The price of Zymeworks BC Inc (NASDAQ:ZYME) shares last traded on Wall Street fell -0.23% to $8.52.
ZYME stock price is now -4.34% away from the 50-day moving average and -6.12% away from the 200-day moving average. The market capitalization of the company currently stands at $607.31M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On January 04, 2023, H.C. Wainwright reiterated its ‘Neutral’ rating on the stock by increasing its target price from $10 to quote $8, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Galbraith Kenneth, Chair & CEO sold 5,706 shares of the company’s stock on Jan 08 ’24. The stock was sold for $63,996 at an average price of $11.22. Upon completion of the transaction, the Chair & CEO now directly owns 23,762 shares in the company, valued at $0.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 08 ’24, Chief Scientific Officer Moore Paul Andrew sold 2,339 shares of the business’s stock. A total of $26,233 was realized by selling the stock at an average price of $11.22. This leaves the insider owning 7,367 shares of the company worth $62766.84. A total of 7.29% of the company’s stock is owned by insiders.
During the past 12 months, Zymeworks BC Inc has had a low of $6.01 and a high of $13.14. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 6.92, and a quick ratio of 6.92. The fifty day moving average price for ZYME is $8.8841 and a two-hundred day moving average price translates $9.082225 for the stock.
The latest earnings results from Zymeworks BC Inc (NASDAQ: ZYME) was released for 2024-03-31. The net profit margin was -249.63% and return on equity was -27.64% for ZYME. The company reported revenue of $10.03 million for the quarter, compared to $35.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -71.81 percent.
